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Background: Little is known about limb muscle abnormalities in mild COPD. Inactivity and systemic inflammation
could play a role in the development of limb muscle dysfunction in COPD. The objective of the present study was
to characterize quadriceps function, enzymatic activities and morphometry, levels of plasma inflammatory markers
and physical activity levels in daily life (PAdl) in patients with mild COPD (GOLD 1).
Methods: Mid-thigh muscle cross-sectional area (MTCSA), quadriceps strength, endurance, fiber-type distribution,
capillarity, pro-angiogenesis factors (VEGF-A, angiopoietin I and II) and muscle oxidative capacity were assessed in
37 patients with mild COPD and 19 controls. Systemic inflammatory markers (CRP, IL-6, TNF-α, Fibrinogen, SP-D)
and PAdl were assessed.
Results: MTCSA, quadriceps strength and endurance were not different between COPD and controls. Capillarity
and muscle oxidative capacity were all preserved in mild COPD. Reduced pro-angiogenesis factor mRNA expression
was seen in COPD. The level of moderately active intensity (>3 METs) was significantly lower in mild COPD and, in
multiple regression analyses, the level of physical activity was a determinant of muscle oxidative capacity and
capillarization. No between-group differences were found regarding muscle oxidative stress while circulating IL-6
levels were elevated in mild COPD.
Conclusions: The quadriceps muscle function was preserved in mild COPD although a reduced potential for
angiogenesis was found. The reduced level of daily activities and evidence of systemic inflammation in these
individuals suggest that these factors precede the development of overt limb muscle dysfunction in COPD.
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Chronic obstructive pulmonary disease (COPD) is often
accompanied by important systemic consequences such
as limb muscle dysfunction [1]. Limb muscle abnormal-
ities in COPD include atrophy, weakness and increased
fatigability [2-5]. At the morphological level, reduced
proportion of oxidative fibers in conjunction with a rela-
tive increase in glycolytic fibers and reduced capillarity
were also observed in the vastus lateralis of patients with
moderate to severe COPD [6-8]. As a result of these mor-
phological modifications, alterations of muscle metabolic* Correspondence: francois.maltais@med.ulaval.ca
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reproduction in any medium, provided the orprofile, in favor of a predominant glycolytic metabolism,
are seen during exercise in these patients [9,10]. The
occurrence of limb muscle weakness and atrophy in
COPD is not a trivial event because it contributes to ex-
ercise intolerance [11] and premature mortality [12] in
this disease.
Why patients with COPD are vulnerable to the develop-
ment of limb muscle functional and morphological distur-
bances is an important question to address if we wish to
unravel the causes of this key systemic manifestation of the
disease. Limb muscle dysfunction is likely to be multifac-
torial in nature, involving factors such as deconditioning,
systemic inflammation and oxidative stress [13], hypox-
emia [8] and nutritional imbalance.l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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function in COPD might provide useful insights about
its underlying mechanisms of development. For example,
if reduced physical activity and systemic inflammation
were mechanistically linked to the development of limb
muscle dysfunction, one would expect them to precede
the development of limb muscle dysfunction. Studies
reporting about limb muscle dysfunction in COPD mostly
involve patients with advanced disease in whom inactivity,
systemic inflammation and limb muscle dysfunction are
well established making it impossible to know which one
came first. In this investigation, we studied limb muscle
function, enzymatic activities and morphometry in pa-
tients with mild COPD (GOLD 1) thinking that this would
provide insights about the potential contribution of sys-
temic inflammation, muscle oxidative stress and physical
inactivity to the development of any muscle abnormalities.
Our hypothesis was that systemic inflammation and phys-
ical inactivity would antedate overt evidence of limb
muscle dysfunction in COPD and, as such, could be con-
sidered as mechanistically involved in this process.
Accordingly, we measured i) mid-thigh muscle cross
sectional area (MTCSA), ii) quadriceps strength and en-
durance, fiber type proportion and surface, capillarity,
oxidative capacity, pro-angiogenesis factors and oxida-
tive stress, iii) levels of plasma inflammatory markers
and iv) physical activity levels in daily life (PAdl) in
patients with mild COPD as well as in age-matched
healthy control subjects.
Methods
See Additional file 1 for further information.
Subjects
We studied 37 patients with GOLD 1 COPD [14] pre-
senting a history of smoking (≥ 15 pack-years). Nineteen
healthy age-matched subjects with normal spirometry and
a history of smoking (≥ 15 pack-years) served as controls.
None of them were involved in a previous study. Activity-
related dyspnea was assessed by the Baseline Dyspnea
Index (BDI) [15]. The research protocol was approved by
the institutional ethics committee (Comité d’éthique,
Institut Universitaire de cardiologie et de pneumologie
de Québec, approval 20378) and all of the participants
signed an informed consent prior to study enrolment. The
sponsor (Boehringer Ingelheim and Pfizer) was not in-
volved in the study design, data collection, analysis or in-
terpretation. The sponsor had the opportunity to read and
comment on the manuscript with no obligation for the au-
thors to incorporate any suggestion into the final version.
Study design
Participants were characterized during a first visit with
pulmonary function tests, and measurements of bodycomposition, MTCSA, quadriceps muscle strength and
endurance. Comorbidities were assessed using a struc-
tured questionnaire and by medical chart review. During
this initial visit, they also performed an incremental shut-
tle walking test. Following ≥ 72-hrs, but within a week of
the first visit, a needle biopsy of the quadriceps was per-
formed and blood was sampled to measure systemic in-
flammatory biomarkers. Finally, participants had to wear a
physical activity monitor for 6 to 8 days.
Pulmonary function testing
Standard pulmonary function tests, including lung vol-
umes and diffusion capacity (DLCO) were obtained accord-
ing to previously described guidelines [16] and related to
predicted normal values [17]. Similarly, spirometry was
performed according to guidelines [16] and related to pre-
dicted normal values [18].
Body composition measurements
Body composition was measured at a standardized period
of the day in a non-fasted state via direct bioelectrical
impedance (In Body 520, Biospace Co., Beverly Hills, CA).
Mid-thigh muscle cross-sectional area
Computed tomography was performed in the supine pos-
ition and MTCSA was determined halfway between the
pubic symphysis and the inferior surface of the femoral
condyle.
Quadriceps muscle strength and endurance
Strength measurements
Potentiated quadriceps twitch force (TwQpot) of the domin-
ant leg was measured by supramaximal magnetic stimula-
tion of the femoral nerve 3 seconds following an isometric
maximal voluntary contraction of the quadriceps (MVC) as
previously reported [19].
Endurance protocol
Quadriceps endurance was evaluated according to an
adapted version of the protocol previously reported by
Allaire and colleagues [20]. It was defined as the time
during which an isometric contraction at 50% of prede-
termined MVC could be maintained.
Incremental shuttle walking test (ISWT)
Peak oxygen uptake (VO2) was determined during a
symptom-limited incremental shuttle walking test. The
original protocol previously validated in COPD [21] was
adapted to include 3 additional walking cadences in order
to allow every participant to reach symptom limitation.
During the test, subjects wore a facemask, linked to a
portable gas exchange analyzer (Oxycon Mobile, Viasys
Healthcare, Jaeger, Germany). Patients were allowed to
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dardized encouragements were provided to the patients.
Muscle biopsy
Needle biopsies of the quadriceps were performed after
30-min of immobilization as described by Bergström
[22] and as routinely done in our laboratory [10]. Muscle
specimens were immediately frozen in liquid nitrogen
and stored at −80°C for future analysis. From these
muscle samples, fiber typing and surface areas were
determined. The cross-sectional area of each fiber-type
was calculated based on 40 randomly selected fibres of
each type [23]. Muscle capillarity and pro-angiogenesis
factors (vascular endothelial growth factor A [VEGF-A],
angiopoietin I [Ang-I], angiopoietin II [Ang-II]) were mea-
sured. Finally, quadriceps oxidative (citrate synthase [CS],
hydroxyacyl-coenzyme A dehydrogenase [HADH]) and
glycolytic (phosphofructokinase [PFK]) enzymatic activity
was assessed as well as muscle oxidative stress. See
Additional file 1 for more details. [Detailed methods used
to analyze fiber typing, muscle surface area, muscle capil-
larity, enzymatic activity, real-time PCR and oxidative
stress].
Systemic inflammation markers
Plasma levels of systemic inflammatory markers (TNF-α,
IL-6, CRP, Fibrinogen, SP-D) were measured from ante-
cubital venous blood sample.
Levels of physical activity
Physical activity in daily life was monitored during 6 to
8 consecutive days via a portable device (SenseWear®
ArmBand, Bodymedia inc., Pittsburgh, USA) worn on
the right upper arm. Physical activity was further charac-
terized by time and energy expenditure associated with
at least moderate intensity (>3 METs). We report the
mean daily values over the period of measure.
Statistical analysis
All variables are expressed as means ± SD. Comparisons
between the two groups for baseline characteristics, muscle
functional and morphometric properties, level of oxidative
stress and systemic inflammation were performed using
unpaired t-test. The homogeneity of variances was ana-
lysed with the Brown-Forsythe test. Multiple regression
analyses were performed to identify potential determinants
of quadriceps MVC, oxidative capacity (CS activity) and
capillary to fiber ratio. Independent variables that were
used in this model included age, sex, smoking history
(pack-years), fat-free mass index (FFMI), forced expiratory
flow in 1 s (FEV1) % predicted, forced vital capacity (FVC)
% predicted, total lung capacity (TLC) % predicted,
functional residual capacity (FRC) % predicted, inspira-
tory capacity (IC) % predicted, residual volume (RV) %predicted, DLCO % predicted, plasma IL-6 level, muscle
oxidative stress indices, number of steps per day, energy
expenditure > 3 METs and daily time > 3 METs. IL-6
was used in this model because it was the only inflamma-
tory biomarker that was significantly increased in COPD.
Beside this statistical consideration, IL-6 is the inflamma-
tory biomarkers with the strongest association with im-
portant clinical outcomes such as mortality, in comparison
with several other biomarkers, including TNF-α, CRP,
fibrinogen and SP-D [24,25]. A statistical level of signifi-
cance of 0.05 was used for all analysis. The data were ana-
lyzed using the statistical package program JMP (Version
8.0.1, SAS Institute Inc., Cary, NC).
Results
Subjects
Characteristics of the participants are presented in Table 1.
Patients with mild COPD displayed more activity-related
dyspnea in addition to mildly increased lung volumes and
decreased diffusion capacity. Total smoking exposure
tended to be lower in controls but this did not reach stat-
istical significance. Peak VO2 was similar between the two
groups. Comorbid conditions (hypertension, dyslipidemia,
osteoporosis, anxiety) were similarly distributed between
the two groups (Additional file 1) [Comorbidities for
which participants were pharmacologically treated in pa-
tients with COPD and healthy controls].
Quadriceps cross-sectional area and function
No difference was found in MTCSA between patients with
mild COPD and healthy controls (Figure 1A). Likewise,
MVC, TwQpot and endurance were all similar between pa-
tients with mild COPD and controls (Figure 1B-D).
Quadriceps intrinsic characteristics
Fiber typing and surface areas
The fiber type distribution was similar between controls
and patients with COPD, showing a slight type I fiber
predominance over type II for both groups (Table 2).
The respective mean muscle surface area occupied by type
I and II fibers were not different between mild COPD and
controls.
Muscle capillarity and angiogenesis
The number of capillaries in contact with type I and
type II muscle fibers were not different between groups
(Table 2). A similar conclusion was reached when taking
into account the surface area of type I and II fibers.
The mRNA expressions of the pro-angiogenesis factors
are provided in Figure 2. When compared with healthy
controls, VEGF-A (p < 0.001), angiopoietin I (p = 0.002)
and II (p = 0.01) mRNA expression levels were lower in
patients with mild COPD.
Table 1 Subject characteristics
Controls (n =19) Mild COPD (n =37)
Age, yr 62 ± 8 65 ± 6
Male, % 69 68
BMI, kg/m2 27 ± 4 27 ± 4
Pack-years 36 ± 17 44 ± 21
BDI, (0–12) 10.6 ± 1.3 9.0 ± 1.6**
Pulmonary function
FEV1, L 3.13 ± 0.70 2.76 ± 0.64*
% predicted 110 ± 19 96 ± 11**
FVC, L 3.91 ± 0.83 4.50 ± 0.98*
% predicted 104 ± 21 117 ± 15*
FEV1/FVC, % 81 ± 4 62 ± 6**
FEF25-75%, % predicted 101 ± 37 43 ± 14**
IC, % predicted 113 ± 16 114 ± 18
TLC, % predicted 102 ± 14 112 ± 11*
FRC, % predicted 94 ± 24 112 ± 23*
RV, % predicted 88 ± 19 107 ± 22*
DLCO, % predicted 97 ± 18 82 ± 19*
Body composition
FFMI, kg/m2 19.1 ± 2.4 18.6 ± 2.3
FMI, kg/m2 8.6 ± 3.6 8.3 ± 2.6
Functional capacity
_VO2 peak, mL•kg
1•min-1 27.5 ± 6.7 25.6 ± 4.8
_VO2 peak, L•min
-1 2.1 ± 0.6 1.9 ± 0.6
Exercise limiting symptoms
Dyspnea, Borg score [0–10] 6.0 ± 2.0 6.9 ± 1.6
Leg fatigue, Borg score [0–10] 4.1 ± 1.7 5.3 ± 2.3
Definitions of abbreviations: BMI Body mass index, BDI Baseline dyspnea index,
FEV1 forced expiratory volume in one second, FVC forced vital capacity,
FEF25-75% forced expiratory flow between 25 and 75% of FVC, IC inspiratory
capacity, TLC total lung capacity, FRC functional residual capacity, RV residual
volume, DLCO diffusion capacity, FFMI Fat-free mass index, FMI Fat mass index,
_VO2 oxygen uptake. Values are mean ± SD. *p < 0.05 vs. healthy controls;
**p < 0.0001 vs. healthy controls.
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The activity of CS was significantly higher in patients with
mild COPD while the activity of HADH (oxidative) and
PFK (glycolytic) were similar between groups (Table 2).
Oxidative stress
We found no differences between patients with mild COPD
and controls for the muscle oxidative stress (Table 2).
Systemic inflammation
Plasmatic levels of IL-6 were significantly higher in pa-
tients with COPD and CRP levels tended to be higher
(p = 0.08) when compared with healthy controls. On the
opposite, plasmatic levels of fibrinogen were higher in
healthy controls (Table 3).Levels of physical activity
Levels of physical activities in daily life are reported in
Figure 3. Patients with COPD had similar daily step
count when compared with healthy controls. However,
when accounting for the intensity of daily life activities,
patients with mild COPD showed a decreased amount
of at least moderate intensity (> 3 METs) physical activ-
ities in daily life. Accordingly, mean daily time dedicated
to at least moderate intensity daily activities was signifi-
cantly reduced in patients with mild COPD.
Correlates of quadriceps muscle function
In multiple regression analysis, quadriceps MVC was
positively associated with male gender (p = 0.03) and
FFMI (p = 0.003) and negatively with FRC (p = 0.002).
Altogether the model explained 73% of the variance in
MVC. CS activity was positively associated with energy
expenditure > 3 METs (p < 0.001) and daily time > 3 METs
(p = 0.007) with a total r2 = 0.53. The capillary-to-fiber
ratio was positively associated with number of steps per
day (p = 0.045), energy expenditure > 3 METs (p < 0.001)
and daily time > 3 METs (p = 0.007) with a total r2 = 0.49.
Plasma IL-6 levels and indices of muscle oxidative stress
did not emerge as significant determinants of quadriceps
MVC, oxidative capacity and capillarization.
Discussion
This study is the first to directly evaluate both, func-
tional and intrinsic muscle properties exclusively in pa-
tients with mild (GOLD 1) COPD. The main finding of
this study was that muscle mass and function, as well as
morphometric and enzymatic properties were generally
preserved in patients with mild COPD when compared
with healthy controls of similar age and smoking history.
Despite this, subtle muscle abnormalities were already
present in GOLD 1 patients with reduced expression of
pro-angiogenesis factors. The findings that the level of
physical activity of at least moderate intensity was already
decreased in these patients and its correlation with muscle
MVC and capillarity support a role for reduced physical
activity in the initiation of limb muscle dysfunction in
COPD.
Quadriceps function and morphometry
Reduced muscle strength and endurance were previously
reported in patients with GOLD 1 and 2 COPD [26]. One
asset of the present study is that only patients with GOLD
1 COPD were enrolled, allowing to conclude about the
preservation of muscle mass, strength and endurance in
this specific patient population.
Our data suggests that fiber type shifting and meta-
bolic alterations are not early events in the process lead-
ing to limb muscle dysfunction in COPD. This finding is




























































Figure 1 Individual values for mid-thigh cross-sectional area (MTCSA, panel A), maximal voluntary contraction of the quadriceps (MVC,
panel B), mean potentiated quadriceps twitch force at baseline (TwQpot, panel C), time to exhaustion during an isometric contraction
at 50% of MVC (QuadEnd, panel D) in patients with mild COPD (open dots) and controls (filled dots). The horizontal lines represent group
mean values.
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with GOLD 3 and 4 COPD [27,28]. Furthermore, the
proportion of type I fibers in our patients was well be-
yond the proposed pathological threshold of 27% [27],
highlighting that muscle fiber type shifting occurs in
more advanced disease. Lastly, evidence of reduced oxi-
dative enzyme activities were not found in another study
involving patients with mild to moderate COPD [29].
Our results about the preservation of muscle capillari-
zation in mild COPD are consistent with a recent study
reporting a similar number of capillaries in contact with
type I and II muscle fibers between patients with mild
COPD and healthy controls in the tibialis anterior [30].
Despite this, a decreased mRNA expression level of pro-
angiogenesis factors was found in COPD. The reduced
quadriceps VEGF-A mRNA expression is consistent with
a previous report [31]. In contrast to our findings, elevated
angiopoietin II mRNA expression level was previously re-
ported in the quadriceps of patients with severe COPD
[32]. A negative association between angiopoietin II mRNA
expression and FEV1 was also observed in this study [32]
suggesting that the divergent conclusions reached about
the quadriceps angiopoietin II expression could well be ex-
plained by differences in disease severity between study
populations. Muscle angiogenesis is regulated by oxidative
stress and inflammation [32], two features that are more
likely to predominate in advanced COPD or during diseaseexacerbation. As such, the angiogenesis status of the quad-
riceps may differ according to disease severity.
Skeletal muscle angiogenesis is a highly regulated process
involving several coordinated signaling pathways, including
VEGF and the angiopoietin system whose activation pre-
cede and promote the formation of new capillaries [33].
Considering the influence of exercise on these key angio-
genesis regulating pathways, reduced physical activity level
emerges at a likely explanation for the reduction in an-
giogenic regulating pathways in patients with GOLD 1
COPD. In the absence of decreased capillarization, we
could only speculate on the significance of the reduced
pro-angiogenesis factors. One possibility is that bio-
chemical regulation of the angiogenic process precedes
the observable changes in capillarization [34]. This in-
terpretation implies that patients with COPD could be
vulnerable in situation where an increase capillarization
would be required such as during hypoxemia. Alterna-
tively, it can be submitted that muscle capillarization is
fairly stable and relatively insensitive to the downregula-
tion in angiogenic growth factors at this stage of the
disease [35].
Mechanisms of limb muscle dysfunction in mild COPD
Similarly to other investigators [31,36-38], we found only
equivoqual evidence of systemic inflammation in this
population of mild COPD. Overall, our inflammatory
Table 2 Quadriceps muscle characteristics
Controls Mild COPD p-value
Fiber type distribution
Type I fibers, % total fibers 57 ± 14 55 ± 13 0.59
Type II fibers, % total fibers 43 ± 14 45 ± 13 0.59
Fiber type area
Type I fibers, μm2 3403 ± 2691 2486 ± 3416 0.33
Type II fibers, μm2 2635 ± 1868 1919 ± 2683 0.32
Total, μm2 6038 ± 4503 4405 ± 6079 0.32
Muscle capillarity
Type I fibers, capillary per fiber 3.80 ± 1.24 3.33 ± 1.04 0.15
Type II fibers, capillary per fiber 2.90 ± 1.04 2.63 ± 0.90 0.35
Total, capillary per fiber 3.38 ±1.09 2.92 ± 0.87 0.10
Muscle capillarity to fiber
area ratio
Type I fibers, capillary per
fiber μm2
1.46 ± 1.56 2.00 ± 1.16 0.16
Type II fibers, capillary per
fiber μm2
1.70 ± 1.56 2.51 ± 1.51 0.08
Total, capillary per fiber μm2 1.91 ± 1.78 2.35 ± 1.24 0.30
Muscle enzymatic activity
Oxidative profile
HADH, μmol•min-1•g muscle-1 2.98 ± 2.56 3.83 ± 4.35 0.47
CS, μmol•min-1•g muscle-1 11.86 ± 6.10 14.49 ± 3.66* 0.04
Glycolytic profile
PFK, μmol•min-1•g muscle-1 34.59 ± 9.04 31.98 ± 8.32 0.29
Muscle oxidative stress
4-HNE, AU 0.99 ± 0.35 1.24 ± 0.67 0.14
OxyBlot®, AU 0.74 ±0.57 1.22 ± 1.46 0.19
Definitions of abbreviations: HADH hydroxyacyl-coenzyme A dehydrogenase,
CS citrate synthase, PFK phosphofructokinase, 4-HNE 4-hydroxynonenal,
















































Figure 2 Individual values of quadriceps mRNA expression for
vascular endothelial growth factor A (VEGF-A, panel A),
angiopoietin I (Ang I, panel B) and angiopoietin II (Ang II, panel
C) in patients with mild COPD (open dots) and controls (filled
dots). The horizontal lines represent group mean values. *Indicates
statistically significant difference between the two groups (see text
for exact p values).
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in showing that IL-6 elevation is very consistent in COPD
[38]. Our findings are also congruent with a previous
study showing that TNF-α and surfactant-D protein
(SP-D) levels are not increased in GOLD 2–4 COPD com-
pared to smokers with normal lung function while fibrino-
gen and CRP levels are highly variable in COPD [38]. The
finding of a reduced plasma fibrinogen level in GOLD 1
COPD was unexpected. Fibrinogen elevation was reported
in a subset of the ECLIPSE cohort involving patients with
GOLD 2–4 COPD, in comparison smokers with normal
lung function [38]. However, significant overlap between
COPD and controls exists in such a way most patients
with COPD have normal fibrinogen levels [37]. Another
point to consider in interpreting this finding is that our
investigation involved patients with GOPD 1 COPD, for
whom little information exists about the inflammatory
status. Lastly, the relative small sample size of ourinvestigation should be considered in interpreting the in-
flammatory biomarker data.
In the context that muscle oxidative stress was not
present in patients with GOLD 1 COPD and because
plasma IL-6 and indices of muscle oxidative stress were not
associated with muscle function and capillarization, our re-
sults do not support the thesis that systemic inflammation
or muscle oxidative stress initiate the establishment of limb
muscle dysfunction associated with COPD.
Table 3 Levels of plasma inflammatory markers
Controls Mild COPD p-value
Systemic inflammation
CRP, mg•L-1 1.44 ± 1.36 2.79 ± 3.22 0.08
IL-6, pg•L-1 3.37 ± 2.19 5.04 ± 2.88* 0.03
TNF-α, pg•mL-1 2.37 ± 3.12 2.46 ± 1.53 0.89
Fibrinogen, mg•mL-1 3.45 ± 2.49 2.34 ± 0.63* 0.01
SP-D, ng•mL-1 12.12 ± 7.49 15.83 ± 14.62 0.30
Definitions of abbreviations: CRP C-reactive protein, IL-6 Interleukin-6, TNF-α
Tumor necrosis factor-α, SP-D surfactant protein D. Values are mean ± SD.







































































Figure 3 Individual values for mean daily steps (panel A), mean
daily energy expenditure of at least moderate intensity (> 3
metabolic equivalent (METs)) (panel B) and mean daily time
spent > 3 METs (panel C) in patients with mild COPD (open
dots) and controls (filled dots). The horizontal lines represent
group mean values. *p < 0.05 vs. controls; †p = 0.09 vs. controls.
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femoris surface area and physical activity level in patients
with GOLD 1 COPD in comparison to healthy controls
[39]. Interestingly, and in contrast to the present study,
the smoking exposure of their healthy controls was much
lower than in COPD. This may suggest that smoking by
itself may be associated with reduced muscle mass as
previously suggested [40]. Altogether, these studies would
support the idea that smoking exposure is important in
the early development of limb muscle atrophy in COPD.
Our results provide further confirmation that the level
of moderately intense physical activity is already low in
GOLD I COPD [39,41,42]. The correlative findings be-
tween the level of moderately intense physical activity
and quadriceps MVC and capillarity support a role for
reduced physical activity in the initiation of limb muscle
dysfunction in COPD. This is in line with recent evi-
dences also pointing to the potential role of reduced
physical activity level in the development of quadriceps
weakness in COPD [43].
Methodological considerations
Although our results are based on a relatively limited sam-
ple size, they exclusively pertain to patients with mild
(GOLD 1) COPD. Subjects were extensively characterized
and the muscle profile was well defined. In fact, the levels
of physical activity could be related to intrinsic and func-
tional muscle properties, offering a unique opportunity to
speculate on causal relationship in locomotors muscles al-
terations in early COPD. However, a definitive answer to
this issue could only be answered by longitudinal studies
evaluating the interactions between physical activity and
limb muscle function over time.
Clinical perspectives
Exercise training remains the most relevant strategy to
reverse functional and metabolic impairments occurring
in the skeletal muscle: it is known to partially reverse the
loss of muscle cross-sectional area and improve muscle
capillary density [44], irrespective of the disease severity
when considering GOLD 1 to 4 patients [45]. Accordingly,
our results provide support for the use of pulmonary
rehabilitation in patients with GOLD 1 COPD as they
already show subtle muscle abnormalities and reduced
level of physical activity.
In conclusion the present study indicates that limb
muscle function, fiber type distribution, enzymatic activ-
ities and capillarization was generally preserved in mild
(GOLD 1) COPD. The level of muscle pro-angiogenesis
factors was nevertheless reduced in these patients suggest-
ing that pre-clinical muscle abnormalities were already
present. Our findings also support a role for reduced
physical activity in the initiation of limb muscle dysfunc-
tion in COPD.
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